Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/IIa, Randomized, Double-blind, Dose-ranging, Placebo-controlled Study of the Safety and Immunogenicity of a HSV-2 Vaccine Containing Matrix M-2 Adjuvant in Individuals With Documented Genital HSV-2 Genital Infection

NCT01667341 is registered in ClinicalTrials.gov with Genocea Biosciences, Inc. as lead sponsor.

NCT NCT01667341
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01667341 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/IIa, Randomized, Double-blind, Dose-ranging, Placebo-controlled Study of the Safety and Immunogenicity of a HSV-2 Vaccine Containing Matrix M-2 Adjuvant in Individuals With Documented Genital HSV-2 Genital Infection
Lead sponsor
Genocea Biosciences, Inc.
Phase
Phase 1/2
Overall status
Completed
Start date
July 31, 2012
Completion date
May 9, 2014
Enrollment
143 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

genital herpes simplex type 2